KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Research & Development for 6 consecutive years, with $95.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 2.43% year-over-year to $95.9 million, compared with a TTM value of $475.3 million through Dec 2025, up 51.16%, and an annual FY2025 reading of $475.3 million, up 51.16% over the prior year.
  • Research & Development was $95.9 million for Q4 2025 at Recursion Pharmaceuticals, down from $121.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $129.6 million in Q1 2025 and bottomed at $24.1 million in Q1 2021.
  • Average Research & Development over 5 years is $66.1 million, with a median of $61.3 million recorded in 2023.
  • The sharpest move saw Research & Development soared 133.32% in 2021, then fell 8.93% in 2022.
  • Year by year, Research & Development stood at $48.3 million in 2021, then dropped by 8.93% to $44.0 million in 2022, then surged by 57.99% to $69.5 million in 2023, then soared by 41.52% to $98.3 million in 2024, then decreased by 2.43% to $95.9 million in 2025.
  • Business Quant data shows Research & Development for RXRX at $95.9 million in Q4 2025, $121.1 million in Q3 2025, and $128.6 million in Q2 2025.